A Phase 4 Randomized OpenLabel Trial to Describe the Safety Tolerability and Immunogenicity of 13 Valent Pneumococcal Conjugate Vaccine Formulated in Multidose Vials When Given With Routine Pediatric Vaccines in Healthy Infants in India.
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 08 Oct 2018 Planned End Date changed from 14 Jan 2020 to 3 Feb 2020.
- 08 Oct 2018 Planned primary completion date changed from 14 Jan 2020 to 3 Feb 2020.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting.